# Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

> **NCT02993068** · NA · SUSPENDED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 5200 (estimated)

## Conditions studied

- BARD1 Gene Mutation
- BRCA1 Gene Mutation
- BRCA2 Gene Mutation
- BRIP1 Gene Mutation
- Estrogen Receptor Negative
- HER2/Neu Negative
- MLH1 Gene Mutation
- MSH2 Gene Mutation
- MSH6 Gene Mutation
- PALB2 Gene Mutation
- PMS2 Gene Mutation
- Progesterone Receptor Negative
- RAD51C Gene Mutation
- RAD51D Gene Mutation
- Triple-Negative Breast Carcinoma

## Interventions

- **OTHER:** Educational Intervention
- **OTHER:** Genetic Counseling
- **OTHER:** Genetic Counseling
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT02993068
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2017-04-18
- **Primary completion:** 2026-04-18
- **Final completion:** 2026-04-18
- **Target enrollment:** 5200 (ESTIMATED)
- **Why stopped:** Accrual Limit
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02993068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02993068, "Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02993068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*